Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a…
– Less than 1 in 10 were on any non-statin lipid lowering therapy – – Findings were shared at the National Lipid Association Scientific Sessions – ANN ARBOR, Mich., June 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR)…